Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
TNF Inhibitors
•
Cardiology
•
Cardio-Rheumatology
Would you be hesitant to continue a TNF inhibitor in a patient with stable RA and a history of COPD, Cor Pulmonale, severe reduced RVEF, but LVEF 65%?
Related Questions
How do you approach management of recurrent idiopathic pleuropericarditis?
Do you pursue coronary artery calcium scoring in patients with metabolic risk factors and autoimmune disease in order to guide decisions regarding GLP-1 medications?
In a patient with psoriatic arthritis and recurrent pericarditis, would you combine abatacept or other biologics with rilonacept?
When would you consider referring a patient with suspected cardiac sarcoidosis based on PET and MRI for endomyocardial biopsy given degree of patchy involvement, as opposed to initiating empiric immunosuppressive therapies?
What biologics would you use in a patient with rheumatoid arthritis who developed multiple basal cell carcinomas requiring Mohs surgery while on a TNF-inhibitor and did not respond to rituximab?
Is cimzia an option for patients with latex allergy?
What is your approach to monitoring patients referred for high titer +RF and +CCP but without active symptoms of inflammatory arthritis?
What is a reasonable stepwise approach to diagnostic imaging when there is ongoing concern for cardiac amyloidosis?
What is your typical steroid taper regimen for managing RA flares?
Do you have any experience with compounded iguratimod either as adjunctive therapy or monotherapy for rheumatoid arthritis, Sjogrens, or axial spondyloarthropathy?
